142 related articles for article (PubMed ID: 9665193)
1. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
Brizard F; Chomel JC; Veinstein A; Rivet J; Giraud C; Kitzis A; Guilhot F; Brizard A
Leukemia; 1998 Jul; 12(7):1076-80. PubMed ID: 9665193
[TBL] [Abstract][Full Text] [Related]
2. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
Chomel JC; Brizard F; Veinstein A; Rivet J; Sadoun A; Kitzis A; Guilhot F; Brizard A
Blood; 2000 Jan; 95(2):404-8. PubMed ID: 10627442
[TBL] [Abstract][Full Text] [Related]
3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
5. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
[TBL] [Abstract][Full Text] [Related]
6. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
[TBL] [Abstract][Full Text] [Related]
7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
8. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
[TBL] [Abstract][Full Text] [Related]
9. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
[TBL] [Abstract][Full Text] [Related]
10. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
11. Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
Kitzis A; Brizard F; Dascalescu C; Chomel JC; Guilhot F; Brizard A
Leuk Lymphoma; 2001; 42(5):933-44. PubMed ID: 11697648
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
[TBL] [Abstract][Full Text] [Related]
13. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
14. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
[TBL] [Abstract][Full Text] [Related]
15. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
[TBL] [Abstract][Full Text] [Related]
17. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
Talwar R; Choudhry VP; Jobanputra V; Kucheria K
Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
Qian SX; Li JY; Zhang R; Hong M; Qiu HR; Li L; Xu W; Sheng RL; Wu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):577-81. PubMed ID: 16800946
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
